Market access for orphan drugs: Can your company break through in emerging markets? Find out which emerging markets offer the best investment prospects for orphan drug manufacturers. Get our new report, Orphan Drug...

The biosimilars industry is increasingly focusing its attention on emerging markets, a move that offers both enormous potential and challenges. FirstView’s Biosimilars in Emerging Markets: Opportunities, Challenges...

It’s a $66 billion market—and getting bigger every year. The time is ripe for action. Yet for all the appeal and potential returns of investing in Latin America’s burgeoning branded generics market, there...

Your key to breaking new ground in emerging markets. It’s a case of old versus new: established markets with stagnant, single-digit growth in sales versus double-digit performance in emerging markets. Yet much as the...

In low and middle-income countries, around 17.6 million people each year die of treatable infectious diseases, reproductive health issues, and childhood illnesses. Millions more experience poor quality of life from chronic...

For the pharmaceutical industry, emerging markets are dynamic, full of potential and offer solid growth at a time when established markets are contracting. But they also pose a significant problem: extreme disparities in...